menu
    • menu
    [{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Agenus | Lustgarten Foundation | Oncovir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AGEN2373","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Agenus | Lustgarten Foundation | Oncovir","highestDevelopmentStatusID":"7","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Agenus | Lustgarten Foundation | Oncovir"},{"orgOrder":0,"company":"Agenus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AGEN2373","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agenus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Undisclosed"},{"orgOrder":0,"company":"Agenus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"AGEN2373","moa":"||Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.8500000000000001,"dosageForm":"Injection","sponsorNew":"Agenus \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Gilead Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals for AGEN2373

    Menu

    AGEN2373

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                            Country arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                            Country arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGEN2373,Balstilimab,Cyclophosphamide,GVAX Pancreatic Cancer Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Agenus | Lustgarten Foundation | Oncovir

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectabl...

                            Details : AGEN2373 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 20, 2025

                            Lead Product(s) : AGEN2373,Balstilimab,Cyclophosphamide,GVAX Pancreatic Cancer Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Agenus | Lustgarten Foundation | Oncovir

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Agenus

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Agenus

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGEN2373,Botensilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : $1,850.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Agenus CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead

                            Details : Gilead will also receive the exclusive option to license two additional programs: AGEN1223 and AGEN2373. AGEN2373 has demonstrated clinical benefit and has been well tolerated without signs of liver toxicity, an adverse event.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $150.0 million

                            April 05, 2022

                            Lead Product(s) : AGEN2373,Botensilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : $1,850.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Agenus

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Agenus

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGEN2373

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

                            Details : AGEN2373 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 10, 2019

                            Lead Product(s) : AGEN2373

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.